NSE: TORNTPHARM | BSE: 500420

Expensive Performer

Download real time

3987.20 -124.10 (-3.02%)

High volume today

NSE 02 Apr, 2026 3:31 PM (IST)

134,944.9

Market Cap

High in industry

Beta 1Year

Very Low volatility

Torrent Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for TORNTPHARM, BSE:500420 Torrent Pharmaceuticals Ltd.

Search Inside the pdf :

Torrent Pharmaceuticals Ltd.

16 Feb 2026

3987.20

-3.02%

Steady India and currency drip into strong performance

Hold: Torrent Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Torrent Pharma (Torrent) posted a strong show in Q3FY26, driven by its businesses in India (+13.7% YoY) and Brazil (27.5%). INR depreciation too played its part in boosting performance of exports.

Torrent Pharmaceutic.. has an average target of 4169.67 from 7 brokers.

Torrent Pharmaceuticals Ltd.

16 Feb 2026

3987.20

-3.02%

BP Equities Q3FY26 Result Update Torrent Pharmaceuticals Ltd.

Results Update: Torrent Pharmaceuticals Ltd.

BP Wealth

...

Torrent Pharmaceuticals Ltd. is trading above its 200 day SMA of 3762.4

Torrent Pharmaceuticals Ltd.

14 Feb 2026

3987.20

-3.02%

DF/LATAM outperforms; Germany underperforms

Neutral: Torrent Pharmaceuticals Ltd.

Target

Motilal Oswal

Torrent Pharma (TRP) delivered a better-than-expected performance, with 3%/5%/10% beat on revenue/EBITDA/PAT in 3QFY26. Growth was aided by consistent superior execution in domestic formulation (DF)/LATAM, favorable currency benefits in the US, and a lower tax rate.

Torrent Pharmaceuticals Ltd. is trading above its 200 day SMA of 3762.4

Torrent Pharmaceuticals Ltd.

12 Dec 2025

3987.20

-3.02%

Committed towards a healthier tomorrow

Buy: Torrent Pharmaceuticals Ltd.

FundsIndia

Branded generics in India and Brazil contribute 73% of revenue. Chronic and sub-chronic therapies form 76% of India sales.

Number of FII/FPI investors increased from 892 to 905 in Dec 2025 qtr.

Torrent Pharmaceuticals Ltd.

10 Nov 2025

3987.20

-3.02%

Torrent Pharmaceuticals (TRP IN) Q2FY26 Result Update BGx...

Accumulate: Torrent Pharmaceuticals Ltd.

Target

Prabhudas Lilladhar

Torrent Pharmaceutic.. has an average target of 4169.67 from 7 brokers.

Torrent Pharmaceuticals Ltd.

10 Nov 2025

3987.20

-3.02%

BP Equities Q2FY26 Result Update Torrent Pharmaceuticals Ltd.

Results Update: Torrent Pharmaceuticals Ltd.

BP Wealth

...

Torrent Pharmaceuticals Ltd. is trading at high day volume of 810.2K.

Torrent Pharmaceuticals Ltd.

09 Nov 2025

3987.20

-3.02%

Branded generics gaining scale

Hold: Torrent Pharmaceuticals Ltd.

ICICI Securities Limited

Torrent Pharma’s (Torrent) Q2FY26 result was in line with our expectations. While Torrent continues to grow at a faster pace in India (+11.5%), its growth in the US (+15.9%) was driven by new launches like gEntresto; stability in currency has sustained its growth in Brazil (+20.9%).

Torrent Pharmaceuticals Ltd. is trading below its 30 day SMA of 4298.0

Torrent Pharmaceuticals Ltd.

08 Nov 2025

3987.20

-3.02%

Execution gains in DF/LATAM/US

Neutral: Torrent Pharmaceuticals Ltd.

Target

Motilal Oswal

Torrent Pharma (TRP) delivered in-line financial performance for the quarter. YoY growth improved in the US generics and LATAM markets, led by new product launches and steady market share gains in the base portfolio.

Torrent Pharmaceuticals Ltd. is trading below its 30 day SMA of 4298.0

Torrent Pharmaceuticals Ltd.

09 Oct 2025

3987.20

-3.02%

TORRENT PHARMA

Hold: Torrent Pharmaceuticals Ltd.

Recommendation Target

Geojit BNP Paribas

Revenue from the Indian market grew 10.8% YoY to Rs. 1,811cr, led by outperformance in focus therapies. The US market's revenue grew 18.9% YoY to Rs. 308cr, as recent launches achieved the targeted market shares. Market revenue from Brazil rose 11.2% YoY to Rs. 218cr, driven by top brands and the performance of...

Number of FII/FPI investors increased from 892 to 905 in Dec 2025 qtr.

Is Torrent Pharmaceuticals Ltd. worth buying?

163 Votes:

Buy 73.01%

Sell 16.56%

Hold 10.43%

RESEARCH REPORTS

Results Update SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf